Sciwind submits HKEX listing application under Chapter 18A
Sciwind
Metabolic Disease Drug Developer
On September 19, 2025, Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind") submitted an application for listing on the Hong Kong Stock Exchange under Chapter 18A, with Morgan Stanley and CICC serving as joint sponsors.
Founded in 2017, Sciwind is a biopharmaceutical company approaching the commercialization stage, dedicated to addressing the urgent medical needs in the field of weight management. It is about to launch Enoglutide Injection (XW003, its core product) in China. This drug is a potential world's first cAMP-biased GLP-1 receptor agonist, indicated for the treatment of overweight/obesity and type 2 diabetes.
Based on its SciwindCore technology platform, the company has expanded its research from GLP-1 receptor agonists to oral peptides and small-molecule drugs, Amylin peptide analogs, and drugs targeting other innovative targets. Its pipeline also includes XW004, a long-acting once-weekly oral cAMP-biased GLP-1 peptide drug, and XW014, an oral small-molecule cAMP-biased GLP-1 receptor agonist with potential for combination therapy.
Since its establishment, Sciwind has completed multiple rounds of financing. In 2018, it secured RMB 60 million in the Pre-A round and RMB 170 million in the Series A round. In 2021, it raised RMB 250 million in the Series B round, USD 68.7 million in the Series C round, and USD 60 million in the Series C+ round . In 2023, it obtained RMB 410 million in the Series C++ round, and in 2024, it raised RMB 467.5 million in the Series D round.
Notable participating investors include LYFE Capital, Loyal Valley Capital, IDG Capital, Tencent Investment, Meituan Investment, Legend Capital, Shiyu Capital, Lilly Asia Ventures, Wu Capital, and Haibang Investment.